Thrombosis Research
Volume 121, Issue 2 , Pages 183-191 , 2007

A segment of Staphylococcus aureus clumping factor A with fibrinogen-binding activity (ClfA221–550) inhibits platelet-plug formation in mice

  • Chao-Zong Liu

      Affiliations

    • Department of Pharmacology, College of Medicine, Tzu Chi University, 701, Chung-Yang Road, Sec. 3, Hualien 970, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 3 856 5301x7511; fax: +886 3 856 1465.
    • ,
  • Tur-Fu Huang

      Affiliations

    • Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan
    • ,
  • Po-Jun Tsai

      Affiliations

    • Department of Pharmacy, Dalin Tzu Chi Buddhist General Hospital, Dalin, Chia-Yi County, Taiwan
    • ,
  • Pei-Jane Tsai

      Affiliations

    • Department of Laboratory Medicine and Biotechnology, College of Medicine, Tzu Chi University, Hualien, Taiwan
    • ,
  • Ling-Ya Chang

      Affiliations

    • Department of Pharmacology, College of Medicine, Tzu Chi University, 701, Chung-Yang Road, Sec. 3, Hualien 970, Taiwan
    • ,
  • Mei-Chi Chang

      Affiliations

    • Biomedical Science Team, Chen Kang College of Technology, Kwei Shan, Tao-Yuan County, Taiwan

Received 21 November 2006 ,Revised 1 March 2007 ,Accepted 22 March 2007.

References 

  1. Weisel JW, Stauffacher CV, Bullitt E, Cohen C. A model for fibrinogen: domains and sequence. Science. 1985;230:1388–1391
  2. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest. 1979;64:1393–1401
  3. Marquerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem. 1979;254:5357–5363
  4. Sheraga HA, Laskowski M. The fibrinogen–fibrin conversion. Adv Protein Chem. 1957;12:1–131
  5. Blombäck B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen–fibrin transition in blood coagulation. Nature. 1978;275:501–505
  6. Siebenlist KR, Meh DA, Mosesson MW. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost. 2001;86:1221–1228
  7. Kanaide H, Shainoff JR. Cross-linking of fibrinogen and fibrin by fibrin-stabilizing factor (factor XIIIa). J Lab Clin Med. 1975;85:574–597
  8. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA. 1998;279:1477–1482
  9. Rudnicka AR, Mt-Isa S, Meade TW. Associations of fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial. J Thromb Haemost. 2006;4:2405–2410
  10. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost. 2003;1:2677–2678
  11. Reininger AJ, Reininger CB, Spannagl M, Mellinghoff A, Porr A, Heinzmann U, et al. Effect of fibrinogen substitution in afibrinogenemia on hemorheology and platelet function. Thromb Haemost. 1995;74:853–858
  12. Kreuz W, Meili E, Peter-Salonen K, Haertel S, Devay J, Krzensk U, et al. Efficacy and tolerability of a pasteurized human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apheresis Sci. 2005;32:247–253
  13. Kloczewiak M, Timmons S, Hawiger J. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the γ chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res. 1983;29:249–255
  14. Doolittle RF, Chen R, Lau F. Hybrid fibrin: proof of the intermolecular nature of γ–γ cross-linking units. Biochem Biophys Res Commun. 1971;44:94–100
  15. Yang Z, Mochalkin I, Doolittle RF. A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides. Proc Natl Acad Sci USA. 2000;97:14156–14161
  16. Jiroušková M, Smyth SS, Kudryk B, Coller BS. A hamster antibody to the mouse fibrinogen γ chain inhibits platelet–fibrinogen interactions and FXIIIa-mediated fibrin cross-linking, and facilitates thrombolysis. Thromb Haemost. 2001;86:1047–1056
  17. Scheiner T, Jiroušková M, Nagaswami C, Coller BS, Weisel JW. A monoclonal antibody to the fibrinogen γ chain alters fibrin clot structure and its properties by producing short, thin fibers arranged in bundles. J Thromb Haemost. 2003;1:2594–2602
  18. Jiroušková M, Chereshnev I, Vaananen H, Degen JL, Coller BS. Antibody blockade or mutation of the fibrinogen γ-chain C-terminus is more effective in inhibiting murine arterial thrombus formation than complete absence of fibrinogen. Blood. 2004;103:1995–2002
  19. Farrell DH. Pathophysiologic roles of the fibrinogen gamma chain. Curr Opin Hematol. 2004;11:151–155
  20. Foster TJ, Höök M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 1998;6:484–488
  21. Hawiger J, Timmons S, Strong DD, Cottrell BA, Riley M, Doolittle RF. Identification of a region of human fibrinogen interacting with staphylococcal clumping factor. Biochemistry. 1982;21:1407–1413
  22. McDevitt D, Francois P, Vaudaux P, Foster TJ. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol. 1994;11:237–248
  23. McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Tumer N, McIntire L, et al. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem. 1997;247:416–424
  24. Deivanayagam CC, Wann ER, Chen W, Carson M, Rajashankar KR, Höök M, et al. A novel variant of the immunoglobulin fold in surface adhesins of Staphylococcus aureus: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. EMBO. 2002;21:6660–6672
  25. Liu CZ, Shih MH, Tsai PJ. ClfA221–550, a fibrinogen-binding segment of Staphylococcus aureus clumping factor A, disrupts fibrinogen function. Thromb Haemost. 2005;94:286–294
  26. Liu CZ, Huang HY, Tsai PJ, Shih MH. Blockade of glycoprotein IIb/IIIa by crotavirin, a member of disintegrins, prevents platelet from activation and aggregation by Staphylococcus aureus bacteria. Thromb Res. 2005;116:145–155
  27. Sheu JR, Chao SH, Yen MH, Huang TF. In vivo antithrombotic effect of triflavin, an Arg–Gly–Asp containing peptide on platelet plug formation in mesenteric microvessels of mice. Thromb Haemost. 1994;72:617–621
  28. Chang MC, Lin HK, Peng HC, Huang TF. Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox. Blood. 1998;91:1582–1589
  29. Holmback K, Danton MJ, Suh TT, Daugherty CC, Degen JL. Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. EMBO. 1996;15:5760–5771
  30. Anti-platelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106
  31. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255–258
  32. Chang MC, Huang TF. In vivo effect of a thrombin-like enzyme on platelet plug formation induced in mesenteric microvessels of mice. Thromb Res. 1994;73:31–38
  33. Ni H, Papalia JM, Degen JL, Wagner DD. Control of thrombus embolization and fibronectin internalization by integrin αIIbβ3 engagement of the fibrinogen γ chain. Blood. 2003;102:3609–3614

PII: S0049-3848(07)00119-3

doi: 10.1016/j.thromres.2007.03.019

Thrombosis Research
Volume 121, Issue 2 , Pages 183-191 , 2007

Article Tools

* Image Usage & Resolution